Sigrid Therapeutics raises further SEK10.6 million in oversubscribed rights issue for accelerated SiPore® commercialization – Yahoo Finance

Swedish Health and Wellbeing company on track for 2023 consumer supplement launch and entry into the veterinary market
STOCKHOLM, Jan. 16, 2023 /PRNewswire/ — Sigrid Therapeutics, a Swedish consumer health and wellbeing company today announced that it has raised an additional SEK10.6 million to accelerate commercialization of its SiPore® health and food supplement portfolio. Both current and new investors participated including recently appointed Chairman, Mattias Ankarberg. In addition to the funds, Sigrid views Ankarberg’s vast experience from the consumer industry, most recently at retail giant H&M, as ideal to help diversify its SiPore® technology into the food supplement, veterinary and oral health markets.
SiPore® is a revolutionary patented platform technology consisting of naturally sourced, carefully designed silica particles that limit the breakdown of foods by enzymes in the gut. This enables blood sugar and other metabolic levels to be controlled. The first medical application is in diabetes and pre-diabetes where Sigrid is set to initiate the SHINE clinical trial study this year. However, SiPore® can be easily produced in a wide variety of formats for other health and wellbeing applications.
“In the current climate, the rapid completion and oversubscription of this new fund raise is a sign of confidence in both SiPore´s® huge potential and our commercialization strategy. In addition to our core prediabetes market, we have identified three major areas which can bring cashflow to the company in the near future – dietary supplements, veterinary products for cats and oral health – with these funds we can now implement our plans for each, “says Sana Alajmovic, Sigrid’s Co-Founder and CEO.
“Sigrid has continued to move forward at a high pace. A capsule product has been developed, the consumer pre-launch program is completed, and preparations for the world’s second largest commercial pre-diabetes study SHINE are coming to a close, adds Mattias Ankarberg, Sigrid’s Chairman.
For more information, https://www.sigridthx.com/, or please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396
Email: sana@sigridthx.com
View original content:https://www.prnewswire.com/news-releases/sigrid-therapeutics-raises-further-sek10-6-million-in-oversubscribed-rights-issue-for-accelerated-sipore-commercialization-301721338.html
SOURCE Sigrid Therapeutics
Discover why two FAANG stocks are poised to bounce back in 2023 and beat the market with their current spring-loaded share price discounts, while another looks like a questionable idea today.
The chip sector is getting back on its proverbial feet after a challenging period, but not every stock is a winner.
These half-dozen stocks will account for the lion's share of Berkshire Hathaway's more than $6 billion in dividend income this year.
Don’t just consume food, invest in it.
Futures fell after U.S. markets were closed for the Martin Luther King Holiday. Time to act, carefully, as the rally clears resistance. Tesla faces a big transition.
(Bloomberg) — China tech bulls expect meme-stock icon Ryan Cohen’s foray into Alibaba Group Holding Ltd. to add impetus to the stock, which has increased more than $140 billion in market value in the latest turnaround.Most Read from BloombergChina’s Population Shrinks for First Time Since 1960s in Seismic ShiftChief Executives, Economists Brace for Recession as Davos BeginsEuropean Stocks Rise as US Futures Signal Caution: Markets WrapItaly’s Most-Wanted Mafia Boss Arrested After 30 YearsMicros
In this video, I will be talking about Alibaba (NYSE: BABA), specifically some new price targets from analysts, and how things could evolve in 2023 now that China is reopening. For the full insights, watch the video, consider subscribing, and click the special offer link below.
The technology sector is home to many of the best stocks to buy or watch, although it's slim pickings these days.
After providing investors with a multitude of gains over the last several years, the music was shut off for Netflix shares in 2022. However, in a quick turn of events, Netflix shares have crushed the S&P 500's performance over the last three months.
Select analysts foresee triple-digit gains in the new year for these innovative, fast-paced companies.
Carnival (CCL) emphasizes on strategic deployments and shorter-duration cruises to boost bookings. However, inflationary pressures are a headwind.
In this article, we look at the 12 best oil stocks to buy according to hedge funds. If you want to skip the detailed analysis about the oil industry, go directly to 5 best oil stocks to buy according to hedge funds. As per US Energy Information Administration, the US was categorised as the world’s […]
Hedge fund manager Boaz Weinstein doesn't believe Credit Suisse will default on its debt but if it does, the derivatives trade he has on the bank may win big, highlighting just how hedge funds use volatile markets to try and generate juicy returns. Hedge funds and other speculators borrowed just over a fifth of Credit Suisse's stock in order to short it as of Oct. 31, the highest level since at least 2006, according to S&P Global Market Intelligence. Weinstein told Reuters that he holds a dual long and short position on Credit Suisse's credit default swaps (CDS), derivative contracts that offer insurance protection and pay out when a company defaults on its debt.
After years of delays, Virgin Galactic's spacecraft is due to hit the skies in the second quarter of 2023.
How the economy fares as the Fed sticks with its inflation fight is a hot topic. The big banks are prepping for a downturn.
Recently, Zacks.com users have been paying close attention to AT&T (T). This makes it worthwhile to examine what the stock has in store.
Recently, Zacks.com users have been paying close attention to Tilray Brands, Inc. (TLRY). This makes it worthwhile to examine what the stock has in store.
Sin is in.
Wood's flagship Ark Innovation ETF has shed 55% during the past year and 77% from its February 2021 peak.
Here is how Acer Therapeutics Inc. (ACER) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.

source